ARQT - Arcutis psoriasis therapy Zoryve gets coverage on national regional plans

2023-04-05 11:05:28 ET

• Arcutis Biotherapeutics ( NASDAQ: ARQT ) said its plaque psoriasis cream Zoryve is being covered without prior authorizations by an additional eight national and regional health plans, effective April 1.
• The company noted that, combined with the previously announced coverage from two of the three largest national pharmacy benefit managers and several national health plans, commercial coverage for Zoryve for plaque psoriasis now exceeds 110M commercially covered lives in the U.S.
• "This commercial coverage, which requires no prior authorization, provides a further proof point that our responsible pricing strategy is resonating with payers," said President and CEO Frank Watanabe.

For further details see: